$藥明康德.HK 公告,預計 2022 年淨利潤 88.14 億元,同比增長約 72.91%。公司獨特的 CRDMO(合同研究、開發與生產)和 CTDMO(合同測試、研發與生產)業務模式持續驅動公司高速發展。

The copyright of this article belongs to the original author/organization.

The current content only represents the author's point of view, and has nothing to do with the position of LongPort. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by LongPort, please contact us.

Like